Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.58 USD | -20.62% |
|
-23.89% | -62.47% |
06-07 | Brookline Capital Initiates SAB Biotherapeutics With Buy Rating, $8 Price Target | MT |
05-30 | SAB Biotherapeutics, Inc. Announces Change of Chief Financial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.47% | 23.81M | |
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.72B | |
-18.26% | 20.82B | |
-18.47% | 16.66B | |
-42.36% | 16.36B | |
-14.23% | 16.19B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- SABS Stock
- News SAB Biotherapeutics, Inc.
- Chardan Initiates SAB Biotherapeutics at Buy Rating With $17 Price Target on Medical Platform Potential